Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Anamorelin, a prominent anti-cachexia drug utilized in the treatment of cancer patients, has seen fluctuations in its pricing due to advancements in medical technology and increase···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：392
Sotorasib, an innovative medication targeting specific genetic mutations in non-small cell lung cancer (NSCLC), has emerged as a novel option for treating this disease owing to its···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：364
Sotorasib, a small molecule inhibitor targeting the KRAS G12C gene mutation in non-small cell lung cancer (NSCLC), has garnered significant attention since its debut. Its distincti···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：391
Anamorelin is a pharmaceutical innovation crafted and manufactured by Ono, Japan, which is a therapeutic agent tailored for the treatment of cachexia induced by various diseases. T···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：349
Sotorasib, also known as AMG-510, is an orally bioavailable drug that falls under the category of selective KRAS G12C covalent inhibitors. By locking the KRAS G12C protein in an in···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：363
Sotorasib, a novel small molecule targeted therapeutic agent, presents a promising treatment avenue for patients harboring the KRAS G12C mutation. The KRAS gene plays a pivotal rol···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：436
Sotorasib, a targeted therapy medication for non-small cell lung cancer (NSCLC), is particularly effective for patients carrying the KRAS G12C mutation. By inhibiting the activity ···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：444
Sotorasib, an oral inhibitor targeting the KRAS G12C mutation, is predominantly utilized in the treatment of non-small cell lung cancer (NSCLC). Clinical trials have demonstrated t···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：383
Adlumiz exhibits a diverse array of applications within the realm of medicine, functioning as a pharmacological intervention for the management of cachexia. Pertinently, the questi···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：406
Sotorasib, a novel targeted medication designed specifically for patients with NSCLC carrying the KRAS p.G12C gene mutation, represents a promising therapeutic option for those ind···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：353
Fidaxomicin, a novel antibiotic medication, is specifically designed to combat difficile-associated diarrhea by targeting the resilient strains that have developed resistance to co···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：412
Fidaxomicin is primarily utilized for the treatment of Clostridium difficile associated diarrhea in adults and children aged 6 months and above.Fidaxomicin currently has only origi···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：398
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：[list:visits]2024-09-07
In recent years, Laos has gradually become a major global supply source for generic drugs, leveragin···【more】
Recommended：[list:visits]2026-22-07
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】
Recommended：[list:visits]2026-21-07
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was···【more】
Recommended：[list:visits]2026-20-07
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was···【more】
Recommended：[list:visits]2026-17-07
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos'···【more】
Recommended：[list:visits]2026-16-07
In recent years, Laos generic drugs have gradually come into view of oncology and chronic disease pa···【more】
Recommended：[list:visits]2026-15-07
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
